Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.

Darwish AM.

A A Pract. 2019 Apr 1;12(7):221-222. doi: 10.1213/XAA.0000000000000888.

PMID:
30234515
2.

Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.

Garcia de Lucas MD, Pérez Belmonte LM, Suárez Tembra M, Olalla Sierra J, Gómez Huelgas R.

Diabetes Metab. 2018 Sep;44(4):373-375. doi: 10.1016/j.diabet.2018.05.005. Epub 2018 May 22.

PMID:
29859992
3.

Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.

Fixen CW, Fixen DR.

Expert Opin Pharmacother. 2017 Dec;18(18):2001-2006. doi: 10.1080/14656566.2017.1410539. Epub 2017 Dec 1. Review.

PMID:
29172834
4.

Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.

Schwetz V, Eisner F, Schilcher G, Eller K, Plank J, Lind A, Pieber TR, Mader JK, Eller P.

Wien Klin Wochenschr. 2017 Sep;129(17-18):646-649. doi: 10.1007/s00508-017-1251-6. Epub 2017 Sep 1.

5.

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

de Winter W, Dunne A, de Trixhe XW, Devineni D, Hsu CH, Pinheiro J, Polidori D.

Br J Clin Pharmacol. 2017 May;83(5):1072-1081. doi: 10.1111/bcp.13180. Epub 2017 Jan 31.

6.

Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.

Davidson JA, Sloan L.

Adv Ther. 2017 Jan;34(1):41-59. doi: 10.1007/s12325-016-0434-2. Epub 2016 Nov 16. Review.

7.

Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.

Andrews TJ, Cox RD, Parker C, Kolb J.

J Emerg Med. 2017 Feb;52(2):223-226. doi: 10.1016/j.jemermed.2016.07.082. Epub 2016 Oct 4.

PMID:
27717592
8.

Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model.

Arafa NM, Marie MA, AlAzimi SA.

Chem Biol Interact. 2016 Oct 25;258:79-88. doi: 10.1016/j.cbi.2016.08.016. Epub 2016 Aug 23.

PMID:
27566243
9.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.

Zhou X, Rougée LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, Ruterbories KJ.

Drug Metab Dispos. 2016 Aug;44(8):1184-92. doi: 10.1124/dmd.116.070623. Epub 2016 May 23.

PMID:
27217490
10.

Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.

Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G.

Postgrad Med. 2016 May;128(4):371-80. doi: 10.1080/00325481.2016.1169894. Epub 2016 Apr 7.

PMID:
27002421
11.

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.

Rosenstock J, Chuck L, González-Ortiz M, Merton K, Craig J, Capuano G, Qiu R.

Diabetes Care. 2016 Mar;39(3):353-62. doi: 10.2337/dc15-1736. Epub 2016 Jan 19.

PMID:
26786577
12.

Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.

Polidori D, Capuano G, Qiu R.

Diabetes Obes Metab. 2016 Apr;18(4):348-54. doi: 10.1111/dom.12615. Epub 2016 Jan 25.

13.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.

Lavalle-González FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M.

Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.

PMID:
26579834
14.

Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.

Yang T, Lu M, Ma L, Zhou Y, Cui Y.

Eur J Clin Pharmacol. 2015 Nov;71(11):1325-32. doi: 10.1007/s00228-015-1923-y. Epub 2015 Aug 19.

PMID:
26282731
15.

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

Devineni D, Manitpisitkul P, Murphy J, Skee D, Wajs E, Mamidi RN, Tian H, Vandebosch A, Wang SS, Verhaeghe T, Stieltjes H, Usiskin K.

Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):226-36. doi: 10.1002/cpdd.166. Epub 2014 Oct 27.

PMID:
27140803

Supplemental Content

Loading ...
Support Center